K-103-PA Phase 3 study

A multi center, randomized, single blind study to evaluate the efficacy and safety of K-103-PA compared with indomethacin patch in the treatment of soft tissue pain

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221217

Enrollment

340

Registered

2010-08-23

Start date

2010-08-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Soft tissue pain

Interventions

investigational material(s) Generic name etc : K-103-PA INN of investigational material : Therapeutic category code : 264 Analgesics, anti-itchings, astrigents and anti-inflammatory agents Dosage and

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Soft tissue pain

Exclusion criteria

Exclusion criteria: 1.Patients with history of allergy to indometacin medication 2.Patients with active skin lesions at the intended site of application of the study medication, with bad skin condition, with dermal hypersensitivity Etc

Design outcomes

Primary

Measure	Time frame
Efficacy, safety VAS pain score, adverse event	—

Secondary

Measure	Time frame
Efficacy, safety VAS pain score, global improvement rating, global assessment of study medication satisfaction, adverse event	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026